Drug intelligence / Profile preview

miR-181a-2-3p mimics

Development stage
Preclinical
Lead developer
Fulengene
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral
01

Overview

miR-181a-2-3p mimics are synthetic double-stranded RNA oligonucleotides designed to simulate the biological activity of the endogenous mature microRNA miR-181a-2-3p. As a member of the miR-181 family, this specific strand (the 3p arm of the miR-181a-2 precursor) regulates gene expression post-transcriptionally by binding to the 3' untranslated regions (UTRs) of target mRNAs, leading to translational inhibition or mRNA degradation. In preclinical research, these mimics have demonstrated diverse roles: they inhibit oncogenicity in colon cancer by targeting Stimulator of Interferon Genes (STING), reduce cancer stem cell populations in cervical cancer by targeting SOX2, and provide protective effects in sepsis-induced acute kidney injury by targeting GJB2. Conversely, in gastric cancer, they have been associated with promoting progression via MYLK targeting. These molecules are primarily utilized as research tools to investigate microRNA function and potential therapeutic pathways.

Other names
hsa-miR-181a-2-3p mimicshsa-miR181a-2-3p mimicshsa-miR 181a-2-3p mimicsmicroRNA-181a-2-3p mimicsmicroRNA181a-2-3p mimicsmicroRNA 181a-2-3p mimicsmiR-181a-2-3pmiR181a-2-3pmiR 181a-2-3p
02

Targets

STING (Stimulator of interferon genes protein)MLCK (Myosin light chain kinase)

Beyond the preview

Go deeper on miR-181a-2-3p mimics.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-181a-2-3p mimics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call